Latest News

  • SYNAPSE holds its annual Christmas retreat

    SYNAPSE holds its annual Christmas retreat

      The company’s annual retreat took place this year in Artchimboldi in Barcelona. The team was fully immersed in internal training sessions and strategic discussions. Eva Molero brought us back to 2008, when the company was created, and revisited the first IMI-JU projects that Synapse managed. Looking back over the past years, we discussed the future of the company and reflected on the strong position achieved in the management of ground-breaking biomedical projects, especially around the Innovative Medicines Initiative (IMI). The training sessions were focused on analysis of best practices when it comes to the management of complex distributed project, and …
  • IMI JU funded projects EPAD, ROADMAP and AMYPAD, managed by Synapse, were presented at the Alzheimer Europe Academy

    IMI JU funded projects EPAD, ROADMAP and AMYPAD, managed by Synapse, were presented at the Alzheimer Europe Academy

                On 5th and 6th of December 2017, Alzheimer Europe (AE) hosted its third annual Alzheimer’s Association Academy in Brussels, Belgium. The meeting was attended by nearly fifty organisations, including representatives from AE member organisations, expert speakers and company representatives. For two days 15 experts in the field of AD research presented on various topics, divided into five sessions. We are proud that representatives from EPAD, ROADMAP and AMYPAD, all managed by Synapse, were invited as expert speakers to present their work and the current progress of the projects. More about ROADMAP: https://roadmap-alzheimer.org/  More about EPAD: http://ep-ad.org/ More …
  • Synapse, with colleagues from IQVIA and University of Edinburgh, represents EPAD at the UK Association for Project Management 2017 award ceremony

    Synapse, with colleagues from IQVIA and University of Edinburgh, represents EPAD at the UK Association for Project Management 2017 award ceremony

    The APM Project Manager Awards 2017 were held on the 20th November at Old Billingsgate, London. The awards recognize the very best the profession has to offer. The EPAD project (European Prevention of Alzheimer’s Dementia Consortium) was one of the six finalists in the “Social Project of the Year” category, and the only finalist among all category finalists, representing a research project in the medical field. Sandra Pla from Synapse, with EPAD representatives from IQVIA and the University of Edinburg attended APM Awards evening. It is an enormous accomplishment for EPAD and Synapse to be one of the finalists since …
  • Synapse met the Enriqueta Villavecchia Private Foundation for Child Oncology

    Synapse met the Enriqueta Villavecchia Private Foundation for Child Oncology

    In the frame of our recently launched Social Programme, Synapse has sponsored the Enriqueta Villavecchia Private Foundation for Child Oncology. Last Friday we had the opportunity to meet the team and learn more about their activities. We could understand the impact that disease has, not only on the life of a child, but also on their families, and the difficulties they face every day. The involvement of the team in helping those children and their families is impressive, and the Enriqueta Villavecchia Foundation work is admirable and meritorious. We are proud to be able to support such an initiative. The …
  • HARMONY’s Big Data platform presented at the 2nd General Assembly

    HARMONY’s Big Data platform presented at the 2nd General Assembly

    The Project’s 2nd GA was held in Berlin, Germany, on the 23rd and 24th of October 2017 where the most advanced technology in data sharing was presented to contribute to a better understanding of hematologic cancers. Public and private organizations will contribute data on most hematologic cancers. The use of a common data model will allow to conduct analysis at an unprecedented scale. Synapse is member of the HARMONY’s Project Management Office, and supports the Executive and Steering Committees in facilitating collaboration and ensuring the effective contribution from all partners in this ambitious project. Read more at: press release More …
  • Social Programme

    Social Programme

    Synapse is committed to support research initiatives with an impact on improving the health and quality of life of citizens. In this spirit, Synapse has initiated its Social Programme, which financially supports local initiatives in the biomedical sector with a social impact in the community.
    The following initiatives have received our support so far:   Synapse sponsors ASIMAGA, a Spanish non-profit association created from the concern of families of children affected with the Cri du chat syndrome considered a rare genetic disorder. This syndrome, also known as chromosome 5p deletion syndrome, 5p− syndrome ("Five P Minus") or Lejeune’s …
  • Company Statement

    Company Statement

    Company Statement Click here to read more
  • Synapse launches its Social Programme

    Synapse launches its Social Programme

    Synapse has kicked-off its Social Programme as part of Synapse’s corporate social responsibility to support initiatives related with the citizen’s health care. Synapse’s Social Programme has started funding two local initiatives: ASIMAGA, a Spanish non-profit association created from the concern of families of children affected with the Cri du chat syndrome, which is considered a rare genetic disorder. The Enriqueta Villavecchia Private Foundation for Child Oncology, a non-profit organization from Barcelona (Spain), which provides integral care for children and youngsters suffering from cancer and gives support to their families. More info at: www.synapse/social-programme
  • Synapse is co-author of a Comment reporting about eTOX Project published in Nature Reviews Drug Discovery

    Synapse is co-author of a Comment reporting about eTOX Project published in Nature Reviews Drug Discovery

    Carlos Diaz, CEO of Synapse, and Dr. Montserrat Cases, Project Manager at Synapse, are co-authors of a Comment published in the prestigious scientific magazine Nature Reviews Drug Discovery that summarises the relevance of data sharing for improving the in silico prediction of organ toxicities in the drug development pipeline, the challenges faced and lessons learned during eTOX project. The eTOX project - Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities- is an IMI project which run from January 2010 to December 2016. Article: “Legacy data sharing to improve drug safety …
  • IMI EPAD project has been selected as one of the finalists for APM Project Management Awards 2017 in the category of Social Project of the Year

    IMI EPAD project has been selected as one of the finalists for APM Project Management Awards 2017 in the category of Social Project of the Year

    The APM Project Management Awards 2017, sponsored by RPC UK Ltd, recognises the achievements of the Project Management profession and rewards the work of young project managers and experienced professionals working in complex projects. The EPAD project, in which Synapse is the Project Manager, is finalist in the Category of Social Project of the year. This category is for projects with the specific aim of developing solutions that deliver benefits to society- locally, regionally, nationally and globally. The ceremony will be held on Monday 20th November 2017 at the Old Billingsgate in London. Sandra Pla will be attending on behalf of …
  • Synapse is a core partner of the new IMI-JU project for new drug safety assessment and integrative data analysis research (eTRANSAFE)

    Synapse is a core partner of the new IMI-JU project for new drug safety assessment and integrative data analysis research (eTRANSAFE)

    Synapse is the project manager for the IMI 2 five-year project, Enhancing Translational Safety Assessment through Integrative Knowledge Management (eTRANSAFE). The project officially started on September 1st 2017 while the official kick of will be in Barcelona (Spain) on the 26-27 of the same month. The project aims to develop an advanced data integration infrastructure together with innovative computational methods to improve the security in drug development process. The eTRANSAFE project aims at improving the safety assessment across the drug discovery and development process by applying bioinformatics approaches to shared preclinical and clinical data to systematically analyse the translatability of …
  • Synapse manages new IMI-JU project for Development of Robust and Innovative Vaccines Effectiveness (DRIVE)

    Synapse manages new IMI-JU project for Development of Robust and Innovative Vaccines Effectiveness (DRIVE)

    Synapse participates in the IMI 2 DRIVE project (Development of Robust and Innovative Vaccines Effectiveness) carrying out specific tasks mainly at the project management level. The 5 years project kicked off on the 17th to the 19th July 2017 in the city of Valencia (Spain) and counted with the attendance of the members of the consortium. Along with Synapse, the DRIVE project is formed by a consortium coordinated by Fundación Fisabio (Spain), while other members are the Institut de Recherche pour le Développement (France), P95 CVBA (Belgium), the Università degli Studi di Firenze (Italy), the National Institute for Health and …
  • New IMI-JU project to assess risk posed by deadly lung infections caused by respiratory syncytial virus (RSV)

    New IMI-JU project to assess risk posed by deadly lung infections caused by respiratory syncytial virus (RSV)

    Synapse is the project manager for the RESCEU project (Respiratory Syncytial Virus Consortium in Europe), kicked-off on January 12-13, 2016 in Sitges (Barcelona, Spain), which will investigate serious lung infections caused by respiratory syncytial virus (RSV) that particularly affect babies and older people, and those with weakened immune systems, including cancer patients and people with chronic lung diseases such as emphysema. Diseases caused by respiratory syncytial virus (RSV) are estimated to affect more than 30 million children under five each year throughout the world. There are no specific treatments for RSV and there is no vaccine. Current therapies are focused …
  • New IMI-JU project for better understanding of adverse drug reactions

    New IMI-JU project for better understanding of adverse drug reactions

    Synapse is part of the Project Management team of the TransQST project (Translational Quantitative Systems Toxicology), kicked-off on 23-24 January 2017 in Barcelona (Spain), and which aims to develop novel computational approaches using the best available data from the public and private domains to improve the understanding of adverse drug reactions (i.e. unwanted side effects of medication) in order to reduce significantly patient morbidity, mortality and hospitalisation costs. TransQST will provide innovative methodologies and software tools to leverage the best available data and expertise from both public and private domains to generate and validate novel computational models that will help …
  • New IMI-JU project for better care for patients with hematologic malignancies (HM)

    New IMI-JU project for better care for patients with hematologic malignancies (HM)

    Synapse is part of the Project Management Office of the HARMONY project (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY), which will be kicked-off on 16-17 January 2017 in Salamanca (Spain), and will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS) and pediatric HMs. Building on pre-existing, long-lasting collaborations between Academic institutes and the pharmaceutical industry, HARMONY shall further advance HM management through a more efficient process of …
  • SYNAPSE organises its annual retreat

    SYNAPSE organises its annual retreat

    The company's annual retreat took place this year in December in Espacio Mood in Barcelona. A few internal training pills were provided by some members of SYNAPSE centred on IMI-2, the transition to the new IMI portal, and the key aspects affecting new IMI projects and proposals next year. The meeting followed with specific corporate strategy-focused sessions addressing internal operating procedures and the new challenges for 2017. Aspects such as quality, proficiency and commitment were brought to the table by all members of the team through open and lively discussions. The new year will come with new projects and exciting challenges and we …
  • New IMI-JU project to pave the way for a sustainable platform for the generation and analysis of real world evidence in Alzheimer’s disease

    New IMI-JU project to pave the way for a sustainable platform for the generation and analysis of real world evidence in Alzheimer’s disease

    Synapse is the project manager for the ROADMAP project (Real world Outcomes across the Alzheimer’s Disease (AD) spectrum for better care: Multi-modal data Access Platform), kicked-off on November 16-17, 2016 in Barcelona, which will deliver a series of scalable, transferable data integration methods and tools for patient outcomes, developed and tested through pilot projects, which will provide the foundation for a Europe-wide Real World Evidence (RWE) platform on AD. Successfully delivering therapies to people with AD will also depend on building a sustainable global payer strategy to address challenges around drug access to markets. This will be dependent on the …
  • New IMI-JU project to investigate the value of β-amyloid brain scans as a diagnostic and therapeutic marker for Alzheimer’s disease

    New IMI-JU project to investigate the value of β-amyloid brain scans as a diagnostic and therapeutic marker for Alzheimer’s disease

    Synapse is the project manager for the AMYPAD project (Amyloid imaging to prevent Alzheimer’s disease), kicked-off on October 5-6, 2016 in London, which will investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia. Beta-amyloid (β-amyloid) deposition in the brain is one of the neuropathological hallmarks on the path towards development of Alzheimer’s disease (AD). The recent advent of commercially available β-amyloid PET tracers has opened up new potential for the visualisation of brain β-amyloid in vivo. It may improve an early diagnosis of AD, and, when recognised in a …
  • 1st edition of the Real World Data Epidemiology Summer School was organized in Oxford

    1st edition of the Real World Data Epidemiology Summer School was organized in Oxford

    The Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS, University of Oxford) launched the 1st edition of Real World Data Epidemiology Summer School, sponsored by Synapse Research Management Partners and IMI-EMIF. The course was focused on the review of the existing sources and the basic introductory concepts of pharmacoepidemiology and medical device epidemiology using observational, routinely collected or registry-based data. The Summer School took place on 11th-15th of July in Oxford. The course gathered a large number of participants, pharmacists, clinicians, registry staff, statisticians, epidemiologists, and related MSc/PhD students from the UK, Spain, Sweden, Italy, Hong Kong and other countries. …
  • The Alzheimer’s prevention EPAD project signs up first study recruit

    The Alzheimer’s prevention EPAD project signs up first study recruit

    The EPAD project, one of the major studies in Europe to find interventions that prevent the onset of Alzheimer’s dementia, has recruited its first participant. Julie Duffus, from Edinburgh (Scotland), is the first person to take part in the project. Participants will have regular health checks including blood tests and brain scans. Researchers will also track their thinking skills over time using tests of mental agility. Afterwards, they will be invited to take part in clinical trials aimed at testing interventions that could delay, or even prevent, the onset of dementia. According to Carlos Diaz, project manager of EPAD and …

Recent Tweets


Follow Us